Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Int Wound J ; 17(1): 65-72, 2020 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-31665826

RESUMEN

Platelets contain abundant growth factors and cytokines that have a positive influence on the migration and proliferation of different cell types by modulating its physiopathological processes. As it is known that human umbilical cord blood platelet lysate (UCB-PL) contains a supraphysiological concentration of growth factors, in the present study, we investigated its effectiveness in wound-healing processes. Human UCB-PL was obtained by the freeze/thaw of platelet concentrate (1.1 × 109 platelets/L), and its effect was evaluated on human or mouse endothelial cells, monocytes, fibroblasts, and keratinocytes in different concentrations. Human UCB-PL was observed to have high levels of pro-angiogenic growth factor than peripheral blood platelet-rich plasma. Among the cell lines, different concentrations of human UCB-PL were necessary to influence their viability and proliferation. For L929 cells, 5% of total volume was necessary, while for human umbilical vein endothelial cell, it was 10%. Cell migration on monocytes was increased with respect to the positive control, and scratch closure on keratinocytes was increased with respect to serum-free medium with only 10% of human UCB-PL. We concluded that the human UCB-PL may be useful to produce a large amount of standard platelet concentrates sufficient for several clinical-scale expansions avoiding inter-individual variability, which can also be used as a functional tool for clinical regenerative application for wound healing.


Asunto(s)
Plaquetas/química , Proliferación Celular/efectos de los fármacos , Citocinas/uso terapéutico , Factores de Crecimiento Endotelial/uso terapéutico , Células Endoteliales de la Vena Umbilical Humana/química , Plasma Rico en Plaquetas/química , Cicatrización de Heridas/efectos de los fármacos , Heridas y Lesiones/tratamiento farmacológico , Proliferación Celular/fisiología , Células Cultivadas/efectos de los fármacos , Humanos , Cicatrización de Heridas/fisiología
2.
Oncol Rep ; 38(1): 561-568, 2017 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-28586072

RESUMEN

Non-cytotoxic concentrations of selected chemotherapeutic agents amplify the antigen presentation capacity of dendritic cells (DCs) and are able to increase the immunogenicity of the colon cancer cell lineage HCT­116, as previously demonstrated by our group. Since this functional alteration was associated with changes in gene expression, we aimed to evaluate whether transcriptional changes of tumor cells can be transferred to DCs, increasing their ability to induce a specific antitumor response. Therefore, HCT­116 cells were treated with two different concentrations of 5-fluorouracil (5-FU), and their total RNA was transfected into human monocyte-derived DC, which function was evaluated through their ability to stimulate the proliferation of normal allogeneic T lymphocytes (MLR), and to generate cytolytic T cells. The transfected DCs demonstrated an increased percentage of CD83+, HLA-DR+, CD80+ and CD86+ cells. These phenotypical changes were followed by functional improvement demonstrated by the increased capacity of these DC to induce allogeneic T cell proliferation and to generate specific anti-HCT­116 cytolytic T cells, as demonstrated by IFN-γ production following in vitro challenge with tumor cells. Our results allow us to conclude that treatment of tumor cells with a non-toxic concentration of 5-FU induces immunogenic changes that are transferred to DC by transfection of total RNA.


Asunto(s)
Presentación de Antígeno/efectos de los fármacos , Antimetabolitos Antineoplásicos/farmacología , Vacunas contra el Cáncer/inmunología , Neoplasias del Colon/terapia , Células Dendríticas/inmunología , Fluorouracilo/farmacología , Antimetabolitos Antineoplásicos/uso terapéutico , Vacunas contra el Cáncer/farmacología , Vacunas contra el Cáncer/uso terapéutico , Proliferación Celular/efectos de los fármacos , Neoplasias del Colon/inmunología , Células Dendríticas/metabolismo , Fluorouracilo/uso terapéutico , Células HCT116 , Humanos , Interferón gamma/inmunología , Interferón gamma/metabolismo , ARN/genética , Linfocitos T Citotóxicos/inmunología , Transfección
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA